Market Overview

Rosetta Genomics Launches BRAF Mutation Assay


Rosetta Genomics Ltd. (NASDAQ: ROSG) announces the launch of
a molecular test for BRAF mutation analysis to help personalize therapy
for melanoma and colon cancer patients. This newest assay will
complement its broad offerings so that oncologists can optimize
treatment decisions for their cancer patients.

Rosetta Genomics' BRAF mutation analysis test utilizes highly specific
and sensitive Competitive Allele-Specific TaqMan® (CAST) PCR™ technology
that can detect as little as 0.5% mutated DNA in a large, normal DNA
sample. BRAF mutations occur in up to 50% of malignant melanomas, and
several FDA-approved BRAF inhibitor therapies have been introduced to
the market for use

See full press release


Related Articles (ROSG)

View Comments and Join the Discussion!

Posted-In: News Press Releases

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at